Articles Tagged With: bamlanivimab
-
Bamlanivimab and Etesevimab Injection
Bamlanivimab and etesevimab should be prescribed to treat mild-to-moderate COVID-19 in adults and pediatric patients (age 12 years and older, weight at least 40 kg) who test positive for COVID-19 and are at high risk for progressing to severe disease and/or hospitalization.
-
Bamlanivimab Injection
Bamlanivimab is a neutralizing recombinant IgG1 monoclonal antibody that connects to the receptor-binding domain of the spike protein of SARS-CoV-2. The drug blocks attachment and entry of the virus into human cells.
-
FDA Issues Emergency Use Authorization for Bamlanivimab
While the search for a vaccine continues, the agency adds to the list of stop-gap therapeutics to battle COVID-19.